ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
Ohr Pharmaceutical Inc.
5.39
+0.0000
成交量:
- -
成交額:
- -
市值:
1,524.96萬
市盈率:
-1.70
高:
5.39
開:
5.39
低:
5.39
收:
5.39
資料載入中...
總覽
公司
新聞
公告
公司資料
公司名字:
Ohr Pharmaceutical Inc.
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
http://www.ohrpharmaceutical.com
郵編:
- -
電話:
- -
傳真:
- -
簡介:
Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊,Ohr Pharmaceutical, Inc.是一家製藥公司,專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案,OHR-102眼藥水,是一種新的治療產品,其可以提供一種非侵入性的治療,改善視力預后,而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液,在給定的組合使用Lucentis注射,在多個相的視網膜疾病的治療中,包括濕的AMD,視網膜靜脈阻塞症,增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OHRP/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OHRP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","market":"US","secType":"STK","nameCN":"Ohr Pharmaceutical Inc.","latestPrice":5.39,"timestamp":1562961599999,"preClose":5.39,"halted":8,"volume":0,"delay":0,"floatShares":2445876,"shares":2829248,"eps":-3.163664,"marketStatus":"交易中","change":0,"latestTime":"04-28 12:34:43 EDT","open":5.39,"high":5.39,"low":5.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.163664,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1745870400000},"marketStatusCode":2,"symbolChange":{"newSymbol":"NBSE","executeDate":"2019-07-15"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","floatShares":2445876,"roa":"-18.45%","roe":"-67.07%","lyrEps":-4.693947,"shares":2829248,"dividePrice":0,"high":5.39,"amplitude":0,"preClose":5.39,"low":5.39,"week52Low":1.582,"pbRate":"1.69","week52High":6.28,"institutionHeld":0,"latestPrice":5.39,"eps":-3.163664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.163664,"open":5.39},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ohrpharmaceutical.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":-0.0316},{"period":"3month","weight":-0.0943},{"period":"6month","weight":-0.049},{"period":"1year","weight":0.0936},{"period":"ytd","weight":-0.0605}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊,Ohr Pharmaceutical, Inc.是一家製藥公司,專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案,OHR-102眼藥水,是一種新的治療產品,其可以提供一種非侵入性的治療,改善視力預后,而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液,在給定的組合使用Lucentis注射,在多個相的視網膜疾病的治療中,包括濕的AMD,視網膜靜脈阻塞症,增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。","exchange":"NASDAQ","name":"Ohr Pharmaceutical Inc.","nameEN":"Ohr Pharmaceutical"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OHRP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-07-15","symbol":"OHRP","oldSymbol":"OHRP","newSymbol":"NBSE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1563163200000},{"market":"US","date":"2019-05-15","symbol":"OHRP","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557892800000,"reportTimeType":"","actualEps":-0.4},{"date":"2019-02-04","symbol":"OHRP","type":"split","dateTimestamp":1549256400000,"forFactor":20,"toFactor":1},{"market":"US","date":"2018-08-14","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"","actualEps":-0.01},{"market":"US","date":"2018-05-15","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OHRP\",market:\"US\",delay:false,,,undefined,":{}}}